First Joint Transnational Call for Proposals (JTC 2011) by Translational Cancer Research (TRANSCAN) on the topic “Validation of biomarkers for personalized cancer medicine”.
During the last decade, the understanding of the molecular pathogenesis and heterogeneity of neoplastic diseases has gained enormous progress from the application of high-throughput technologies including genomics, epigenomics, transcriptomics and proteomics. There is a great expectation that these advances will eventually be translated into more sensitive, specific and noninvasive methods and tools for early diagnosis and prediction of response to therapy and outcome as well as into the identification of potential novel therapeutic targets and more selective and effective and less toxic therapeutic agents and interventions as well.
In this up-coming approach, the molecular and patho-physiological characteristics of a single patient and tumour will be measured and tailored tools or agents/strategies/regimens will be used based on particular profiles. This is one of the requirements for this process is undoubtedly the usage of validated biomarkers. While great advances have been made in the discovery of supposed biomarkers, disappointingly few meet acceptable standards of performance or have been translated into clinically applicable evaluate.
Therefore, an urgent need in the field of personalized medicine is the validation of candidate biomarkers emerging from large discovery strategies.
Submission deadline for pre-proposals: 10 February 2012
For further information, please visit our link.
